Dupilumab-associated sezary syndrome
Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Dermatology |
| Subjects: | |
| Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=4;spage=459;epage=462;aulast=Hamp |
| _version_ | 1827783284218658816 |
|---|---|
| author | Austin Hamp Jamie Hanson Albert Alhatem Robert A Schwartz |
| author_facet | Austin Hamp Jamie Hanson Albert Alhatem Robert A Schwartz |
| author_sort | Austin Hamp |
| collection | DOAJ |
| description | Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon. |
| first_indexed | 2024-03-11T15:45:34Z |
| format | Article |
| id | doaj.art-dc48e905d48747a49b4076bca6fdcbf6 |
| institution | Directory Open Access Journal |
| issn | 0019-5154 1998-3611 |
| language | English |
| last_indexed | 2024-03-11T15:45:34Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Dermatology |
| spelling | doaj.art-dc48e905d48747a49b4076bca6fdcbf62023-10-26T06:34:36ZengWolters Kluwer Medknow PublicationsIndian Journal of Dermatology0019-51541998-36112023-01-0168445946210.4103/ijd.ijd_580_22Dupilumab-associated sezary syndromeAustin HampJamie HansonAlbert AlhatemRobert A SchwartzDupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been delineated with the progression to SS. We present an additional case of a patient who was diagnosed with SS following treatment with dupilumab for adult-onset AD and asthma. We examine SS as a possible side effect of dupilumab while also discussing management and theories to explain this phenomenon.http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=4;spage=459;epage=462;aulast=Hampatopic dermatitisdupilumabmycosis fungoidessézary syndrome |
| spellingShingle | Austin Hamp Jamie Hanson Albert Alhatem Robert A Schwartz Dupilumab-associated sezary syndrome Indian Journal of Dermatology atopic dermatitis dupilumab mycosis fungoides sézary syndrome |
| title | Dupilumab-associated sezary syndrome |
| title_full | Dupilumab-associated sezary syndrome |
| title_fullStr | Dupilumab-associated sezary syndrome |
| title_full_unstemmed | Dupilumab-associated sezary syndrome |
| title_short | Dupilumab-associated sezary syndrome |
| title_sort | dupilumab associated sezary syndrome |
| topic | atopic dermatitis dupilumab mycosis fungoides sézary syndrome |
| url | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=4;spage=459;epage=462;aulast=Hamp |
| work_keys_str_mv | AT austinhamp dupilumabassociatedsezarysyndrome AT jamiehanson dupilumabassociatedsezarysyndrome AT albertalhatem dupilumabassociatedsezarysyndrome AT robertaschwartz dupilumabassociatedsezarysyndrome |